计算溶液所需的质量、体积或浓度。
| 活性类型 | 活性值-log(M) | 作用机制 | 期刊 | 参考文献(PubMed IDs) |
|---|
Moligand™ 级 ,适用于对基线干扰要求严格的色谱和分析工作流程。
-80℃储存。特低温运输 。请查阅批次 COA 获取详细规格。
SDS、COA、产品数据表及规格说明书均可下载。可通过批号查询获取批次 COA。
在色谱分析、有机合成和交叉偶联反应领域已被 0 篇同行评审文献引用。
Information
CCT245737 (SRA737, PNT-737) is an orally activeCHK1inhibitor with The IC50 of 1.4 nM. It exhibits >1,000-fold selectivity against CHK2 and CDK1.
Targets
Chk1 (Cell-free assay) 1.4 nM
In vitro
CCT245737 is a potent inhibitor of recombinant human CHK1 with IC50 of 1.4±0.3 nM (mean±SD, n = 3, EZ Reader II assay). There is > 1,000-fold selectivity for CHK1 versus the functionally important kinases CDK1 and CHK2 (IC50=1.26-2.44 and 9.03 μM, respectively), and at least a 90-fold selectivity against cross-reacting kinases such as ERK8, PKD1, RSK1 and 2. CCT245737 potently inhibits cellular CHK1 activity (IC50 30-220nM) and enhances gemcitabine and SN38 cytotoxicity in multiple human tumor cell lines and human tumor xenograft models. It can abrogate an etoposide-induced G2/M arrest. CCT245737 has high cell permeability, as measured by transport across a CaCo2 cell monolayer.
In vivo
Mouse oral bioavailability is complete (100%) with extensive tumor exposure. CCT245737 shows significant single-agent activity against a MYC-driven mouse model of B-cell lymphoma. An i.v. dose of 10mg/kg CCT245737 into BALB/c mice gives a peak plasma concentration of 4μmol/L, with a half-life of 2.86h, an AUC0-∞ of 9.96μmol.h/L, a plasma clearance of 2.1L/h/kg and a large volume of distribution (0.19L). The equivalent oral dose gave an almost identical profile with an AUC0-∞ of 10.4μmol.h/L showing complete oral bioavailability (F = 105%). In a word, CCT245737 shows complete oral bioavailability with linear pharmacokinetics and high tumor/plasma ratios consistent with extensive tumor exposure. Adequate CCT245737 tumor drug exposure takes a significant antitumor activity.
Cell Research(from reference)
Cell lines:The colon tumor cell lines HT29 and SW620, the pancreatic cancer cell line MiaPaCa-2 and the non-small cell lung cancer Calu6 cell line
Incubation Time:96 h
分类树(Taxonomy Tree)
| 界(kingdom) | 有机化合物 |
|---|---|
| 超类(Superclass) | 有机杂环化合物 |
| 类(Class) | 二嗪类 |
| 亚类(Subclass) | 吡嗪类 |
| 中间层级节点(Intermediate Tree Nodes) | 暂无 |
| 直接上位类(Direct Parent) | 氨基吡嗪类 |
| 其他上位类(Alternative Parents) | 仲烷基芳胺 氨基吡啶及其衍生物 吗啉 咪唑内酰胺类 杂芳族化合物 氧环化合物 腈类 二烷基胺 二烷基醚 氮杂环化合物 有机氟化物 碳氢化合物衍生物 烷基氟化物 |
| 分子骨架(Molecular Framework) | 芳香族杂单环化合物 |
| 取代基(Substituents) | 氟化烷基 - 烷基溴化物 - 氨基酸 - 氨基吡嗪 - 氨基吡啶 - 芳香族杂单环化合物 - 氮杂环 - 碳腈 - 氰化物 - 二烷基醚 - 乙醚 - 杂芳香族化合物 - 烃衍生物 - 咪唑内酰胺 - Morpholine - 氰基化合物 - 有机硝基化合物 - 有机氧化合物 - 有机氟化物 - 有机卤化物 - 有机氮化合物 - 有机氧化合物 - 氧杂环 - 氧杂吡嗪烷 - 吡啶 - 二级脂肪胺 - 二级脂肪族/芳香族胺 - 醛基 |
| 描述(Description) | 该化合物属于有机化合物中的氨基吡嗪类。这类化合物具有连接在吡嗪环上的氨基结构。 |
| 外部描述符(External Descriptors) | 暂无 |
| IC50 | Chk1, IC50: 1.4 nM |
|---|---|
| ALogP | 1.46 |
| hba_count | 4 |
| HBD Count | 3 |
| Rotatable Bond | 6 |
| 作用机制 | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | 参考文献 |
|---|